

ICS 11.020
CCS C 59

WS

**INDUSTRY STANDARD OF THE
PEOPLE'S REPUBLIC OF CHINA**

WS/T 485-2016

**Technical regulations for application of antimalarials
(English Translation)**

Issued on: May 20, 2016

Implemented on: October 15, 2016

**Issued by: National Health and Family Planning Commission of the
People's Republic of China**

Table of Contents

Foreword	
1 Scope	
2 Normative references	
3 Terms and definitions	
4 Antimalarial drug use principle	
5 Antimalarial options	
5.1 Antimalarial drug for Plasmodium vivax and oval malaria	
5.2 Antimalarial drug for malaria on the 3rd	
5.3 Antimalarial drugs for falciparum malaria	
5.4 Antimalarial drugs for severe malaria	
5.5 Antimalarials for use in a variety of Plasmodium co-infections	
5.6 Preventive medicine	
5.7 Rest period cure	
6 Antimalarial drug use program	
6.1 Antimalarial use of vivax and ovum malaria programs	
6.2 Antimalarial use of malaria on day 3 Protocol	
6.3 Plasmodium falciparum antimalarial drug use program	
6.4 Severe Malaria use of antimalarial program	
6.5 Pregnant women suffering from malaria use of antimalarial program	
6.6 Periodicidal drug use program	
6.7 Preventive medication program	
Appendix A (Normative) Chloroquine phosphate primaquine phosphate eight days program	
Appendix B (Normative) Piperacillin phosphate primaquine eight days program	
Appendix C (Normative) Artemisinin compound use program	
Appendix D (Normative) Primary amine phosphate eight days program	
Appendix E (Normative) Pyronaridine phosphate three-day program	
Annex F (Normative) Chloroquine phosphate three-day program	
Appendix G (Normative) Piperazine phosphate three days program	
Appendix H (normative) artemisinin injection solution	
Appendix I (normative) pyronaridine phosphate injection solution	
Appendix J (normative) pregnant women within 3 months of pregnancy suffering from falciparum malaria piperazine use program	

Foreword

This standard was drafted in accordance with the rules given in GB/T 1.1-2009.

This standard was drafted. Institute of Parasitic Diseases in Jiangsu Province, China Center for Disease Control and Prevention parasites control, Guangzhou University of Chinese Medicine, Zhongshan Medical College, Zhongshan University.

Drafters of this standard. Gao Qi, Tang Linhua, Fu Linchun, Yu Xinbing, Guan Yayi, Zhou Shui-sen, Xia Zhi Gui, Cao Jun, Zhou Huayun.

Anti-malarial drug use specification

1 Scope

This standard specifies the choice and use of anti-malarial drugs.

This standard applies to medical institutions and disease prevention and control agencies for the prevention and treatment of malaria.

2 Normative references

The following documents for the application of this document is essential. For dated references, only the dated version applies to this article Pieces. For undated references, the latest edition (including all amendments) applies to this document.

WS 259 Malaria diagnostic criteria

3 Terms and definitions

WS 259 and defined by the following terms and definitions apply to this document.

Relapse

Plasmodium vivax or Plasmodium falciparum in the blood of patients with Plasmodium vivax was cleared for several weeks or months after development by P. falciparum dormant in the liver Schizonts, the release of merozoites into the blood for Rift multiplication, re-emergence of clinical symptoms and signs of malaria.

Rest period radical anti-relapsetreatment in endemic areas of malaria, primaquine treatment was used prior to the pre-season season for patients who had had vivax malaria or oval malaria within a year, clearing the possibility of Intrahepatic malaria parasite to prevent recurrence.

Artemisinin-based combination of therapies based on artemisinin; ACTs Compound or combination regimens of artemisinin or its derivatives with one or more other anti-malarial drugs. Abbreviated artemisinin class Compound.

4 Antimalarial drug use principles

The use of anti-malarial drugs should follow the principles of safety, efficiency, reasonableness and standardization. Should be based on the parasite species and its antimalarial drug sensitivity and Patients with clinical symptoms and signs of a reasonable choice of drugs, and should strictly control the dose, treatment and route of administration to ensure that the treatment and prevention effect and Delay the emergence of drug resistance.

5.1 Antimalarial drug for Plasmodium vivax and oval malaria

Preferred chloroquine phosphate primaquine phosphate. Chloroquine phosphate ineffective, the choice of piperaquine phosphate, or pyronaridine phosphate or ACTs plus phosphoric acid Primaquine.